AltPep
Dr. Block has 33 years of experience in the pharma/biotech fields leading clinical development of drugs for a broad range of neurological indications, including Alzheimer’s Disease. He was at Merck for 14 years as Senior Director and Head of Clinical Neuropharmacology. Later he was the Executive Director, US Drug Development/Global Medicine & Science, at AstraZeneca. He has expertise ranging from preclinical and clinical translation, clinic development in all phases, to marketing approval.
This person is not in any offices
AltPep
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. They are currently focusing on CNS disorders, in particular Alzheimer’s Disease (AD). They target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).